Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Diseases
Immunovia announces positive results for next-gen pancreatic cancer test
By
LabPulse.com staff writers
Diagnostics company Immunovia announced positive results for the newest generation of its pancreatic cancer test from a model-development study, announcing that the test achieved both its primary and secondary endpoints.
April 25, 2024
Vertex to pay $25M upfront to scale cell manufacturing technology
By
LabPulse.com staff writers
As part of the deal, Vertex was also willing to pay up to $215 million in milestones achieved in connection with the development of a scaled-up process for fully differentiated islet cells.
April 25, 2024
Scout secures CARB-X grant to advance diagnostic test development
By
LabPulse.com staff writers
Scout, formerly Uh Oh Labs, will advance its point-of-care (POC) diagnostic test for sexually transmitted infections (STIs) with a new $1 million accelerator grant.
April 22, 2024
Quest adds new biomarker test to Alzheimer's portfolio
By
LabPulse.com staff writers
Quest Diagnostics has launched a new blood biomarker test as part of its AD-Detect portfolio of blood tests for Alzheimer's disease risk assessment.
April 23, 2024
Target ALS launches new data portal for research
By
Matt Limb
A nonprofit medical research foundation has launched a data portal designed to help spur scientific breakthroughs for the disease amyotrophic lateral sclerosis (ALS).
April 23, 2024
AI-powered endoscope doubles detection of high-risk esophageal lesions
By
Nick Paul Taylor
Deep learning has doubled the detection of high-risk lesions during routine endoscopies in a clinical trial of more than 3,000 patients in China.
April 17, 2024
Veracyte to share bundle of genomic classifier studies at AUA 2024
By
LabPulse.com staff writers
Veracyte has announced that the American Urological Association's May meeting will feature nine sessions related to evaluations of its prostate cancer and bladder cancer genomic tests.
April 16, 2024
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By
LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
Lipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in study
By
Nick Paul Taylor
Blocking lipid synthesis enhanced the effect of PARP inhibitors on prostate cancer in a preclinical study, pointing to a potential way to make the treatments effective in more patients.
April 15, 2024
Urine test halves use of invasive procedure to monitor bladder cancer
By
Nick Paul Taylor
A urine test can cut the number of cystoscopies necessary to follow up high-risk bladder cancer patients without increasing the risk of recurrence, a study has found.
April 11, 2024
Researchers tweak TB treatment assay to support global use
By
Nick Paul Taylor
Researchers have developed a tuberculosis (TB) treatment assay that could be a faster, simpler method for monitoring patients.
April 10, 2024
Skin biopsy test shows promise for detection of neurogenerative diseases
By
Matt Limb
A simple skin biopsy test has shown a high accuracy rate in detecting an abnormal form of alpha-synuclein, the pathological hallmark of Parkinson's disease and other synucleinopathies, say neurologists.
April 5, 2024
Page 1 of 284
Next Page
